SCHEMBL7003304

SCHEMBL7003304

O=S(=O)(NCCCCCCNc1nsc2nccn12)c1cccc(C(F)(F)F)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F13A1 P00488 8/20 0.73
TGM1 P22735 2/20 0.58
BRAF P15056 3/20 0.49
PTGES O14684 1/20 0.44
RAF1 P04049 1/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TP53 P04637 1/20 0.41
HTR1A P08908 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR7 P34969 1/20 0.40
HTR6 P50406 1/20 0.40
MMP7 P09237 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
MMP8 P22894 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7011955 0.89 F13A1 (0.77) F13A1TGM1BRAFRAF1MAPT
SCHEMBL7004923 0.87 F13A1 (0.77) F13A1TGM1BRAFRAF1
SCHEMBL7005912 0.86 F13A1 (0.79) F13A1TGM1HTR7HTR6
SCHEMBL7004156 0.85 F13A1 (0.77) F13A1TGM1BRAFRAF1KDM4E
SCHEMBL7007806 0.85 F13A1 (1.00) F13A1TGM1BRAFKDM4EHTR1A
SCHEMBL7004823 0.84 F13A1 (0.78) F13A1TGM1CYP2C19
SCHEMBL7005909 0.83 F13A1 (0.79) F13A1TGM1HTR1AHTR2AHTR7
SCHEMBL7004951 0.82 F13A1 (1.00) F13A1TGM1BRAF
SCHEMBL7008810 0.82 F13A1 (0.82) F13A1TGM1BRAFRAF1
SCHEMBL7004277 0.82 F13A1 (0.74) F13A1TGM1HTR2AHTR7HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225007-A1 Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases APOTEX INC. 2003-12-04 US disclosed
EP-1348710-A1 Sulfonamide derivatives of 3-substituted imidazo[1,2-D]-1,2,4-thiadiazoles and 3-substituted-[1,2,4]thiadiazolo[4,5-A]benzimidazole as inhibitors of fibrin cross-linking and transglutaminases Apotex Inc. (CA) 2003-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225007-A1 Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases PIGS, FGB, SERPINE1 F13A1 14/4885TGM1 7/4885BRAF 3474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.